ComparativeIn VitroActivities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile Recurrence | Zendy

Ellie J. C. Goldstein | Zendy; Diane M. Citron | Zendy; Kerin L. Tyrrell | Zendy

Open Access

ComparativeIn VitroActivities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile Recurrence

Author(s) -

Ellie J. C. Goldstein,

Diane M. Citron,

Kerin L. Tyrrell

Publication year - 2013

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02184-13

Subject(s) - clostridium difficile , clostridium , clostridiales , microbiology and biotechnology , clostridiaceae , biology , antimicrobial , 16s ribosomal rna , clostridium infections , bacteria , antibiotics , genetics , toxin

We determined the comparative activity of SMT19969 (SMT) against 162 strains representing 35 well-characterized Clostridium species in clusters I to XIX and 13 Clostridium species that had no 16S rRNA match. SMT MICs ranged from 0.06 to >512 μg/ml and were not species related. SMT might have less impact on normal gut microbiota than other Clostridium difficile infection (CDI) antimicrobials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research